StageZero Life Sciences Announces Commencement of Trading on the OTCQB

TORONTO, ON / ACCESSWIRE / September 27, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) (the "Company" or "StageZero"), a healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through lab developed tests and clinical interventions, is pleased to announce that its common shares have been approved for trading on the OTCQB in the United States under the symbol SZLSF. StageZero commenced trading on the OTCQB on September 23, 2021 while continuing to trade on the TSX Exchange in Canada.

The OTCQB is a premier marketplace for early stage and developing U.S. and international companies that are committed to providing a high-quality trading and information experience for their U.S. investors. Companies are required to be current in their reporting and undergo annual verification and management certification process. Investors can find real-time quote and market information for the Company on www.otcmarkets.com.

"Listing on the OTCQB Market marks an important milestone for StageZero and is the beginning of our investor awareness push into the US market," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences, Ltd. "With US investors now able to easily purchase and trade our common shares and which now significantly expands our attractiveness to institutional groups, we can now embark on a number of planned, virtual, non-deal roadshows in the US marketover the coming months."

About StageZero Life Sciences

StageZero Life Sciences is dedicated to the early detection of multiple diseases through whole blood tests. The Company's next-generation test, Aristotle®, is the first-ever multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. StageZero's full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups, and the Company operates a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, leveraging its specialty in polymerase chain reaction (PCR) testing for the early identification of cancer through blood, StageZero also provides both COVID PCR testing (swab and saliva) and blood test analysis (Antibody testing). For more information, please visit www.stagezerolifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

For further information please contact:

Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com